Summit Therapeutics SMMT Preferred Stock
Preferred Stock at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockValue.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's preferred stock.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's preferred stock?
- Summit Therapeutics (SMMT) reported preferred stock of $0 in Q1 2026.
- What does preferred stock mean?
- The value of shares that have priority over common stock for dividends or assets.
- How do you interpret preferred stock?
- The issuance of preferred stock often signals a capital-raising event that avoids immediate dilution of common shareholders but adds a dividend obligation.
- How does preferred stock compare across companies?
- Commonly used by companies to raise capital without diluting common equity; prevalence varies by capital structure strategy.